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COMPARISON OF CHARACTERISTICS OF COLORECTAL CANCER PATIENTS
ADMITTED EMERGENTLY, URGENTLY OR ELECTIVELY IN WEST VIRGINIA
HOSPITALS BETWEEN 2003-2007
Shah N, Halverson J
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OBJECTIVES: Colorectal cancer poses a significant disease burden inWest Virginia.
Hospitalization followed by surgical resection is the standard curative treatment.
Emergency admissions account for more than 25% of colorectal cancer hospital-
izations nationwide. The aim of this study is to compare characteristics of West
Virginia residents admitted emergently, urgently or electively to West Virginia
hospitals between 2003-2007. Another aimwas to explain the association between
admission type and in-hospital deaths.METHODS: Data from the Healthcare Cost
and Utilization Project (HCUP), State Inpatient Database were investigated. De-
scriptive statistics for admission type, comorbidities, in-hospital death, age and
sex were tabulated; chi-square analyses helped explain differences in characteris-
tics between admission types. Logistic regression was employed to explain differ-
ences in in-hospital deaths between emergency, urgent and elective admissions.
RESULTS: There were 9380 admissions with a primary or secondary diagnosis of
CRC of which 33.1% were emergency admissions, 24.4% urgent and 42.1% elective.
Of the in-hospital deaths more than half (50.5%) the cases were admitted emer-
gently compared to electively (23.1%). Among emergency and urgent admissions
the most common comorbid conditions were diabetes (17.1%), followed by fluid
disorders (6.9%) and hypertension (5.0%). Among elective admissions diabetes
(19.9%) was followed by COPD (4.3%) and hypertension (3.5%). Logistic regression
showed that the odds of in-hospital death were 3.03 times higher for emergency
admission compared to elective after controlling for age, sex, number of comor-
bidities, diagnosis type and payer. CONCLUSIONS: Patients admitted emergently
are more likely to die in-hospital compared to those admitted electively. The large
percentage of patients admitted emergently indicates advanced disease and pos-
sibly failure of timely screening. Comorbid conditions differed by admission type
and need further investigation. Diabetes was the most common comorbid condi-
tion overall and further investigation in diabetics is needed to check screening
behavior and access to screening centers.
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LEARNING THE LESSONS OF ONCOLOGY HTA REVIEWS IN AUSTRALIA & THE
UNITED KINGDOM – A CASE STUDY OF FIVE DRUGS
Lewis S, Dummett H
Double Helix Consulting, London, UK
OBJECTIVES: HTA agencies have different requirements and preferences in terms
of both themodels they receive and the clinical evidence that submission are based
on. Our aimwas to understand what could be learned about the preferences of the
PBAC in Australia and NICE and the SMC in the UK specific to oncology from five
selected case studies. METHODS: Five high-profile cancer drugs, namely Avastin
(bevacizumab), Erbitux (cetuximab), Sprycel (dasatinib), Tykerb/Tyverb (lapatinib)
and Tarceva (erlotinib) were selected as our research sample. All assessment guid-
ance related to the five drugs by NICE, the PBAC and the SMC were reviewed to
examine the rationale behind positive or negative recommendations. Based on the
review, we analysed the agencies’ preferences for oncology HTA submissions.
RESULTS: Avastin has been one of the most rejected drugs among the three agen-
cies, with the exception of PBAC’s recommendation of listing for 1st linemetastatic
colorectal cancer treatment on the condition of a patient access scheme. The in-
crease to the overall drug cost by including Avastin in the treatment regimen has
been the main concern with other negative factors including the inappropriate
choice of comparators.Tykerb received negative recommendations from both
PBAC and SMC for breast cancer due to concerns over small trial population size,
robustness of efficacy evidence as well as high ICER. Between the 5 drugs, 21 HTA
reviews took place, resulting in 11 positive recommendations, 10 rejections and 1
deferred decision for further price negotiation. Out of the positive recommenda-
tions, 4 were based on risk sharing arrangements. CONCLUSIONS: HTA agencies
responddifferently to submissions based on the same clinical dossier. Understand-
ing in detail what the evidence preferences are of the individual agencies is crucial
of the probability of reimbursement is to bemaximised. This understanding should
be fed into clinical development and supplementary evidence plans.
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OBJECTIVES: Considering human factors in new technology is essential to ensure
its acceptance, particularly in underserved communities. This study assessed the
usability of the original (Flash) and new (HTML) versions of a self-administered
familial cancer risk assessment tool- the Jameslink. METHODS: The study was a
randomized, hybrid experimental design involving in-person usability testing of
predominantly lower-income, African American individuals 18 years or older.
Flash and HTML versions of the Jameslink were compared for the outcomes of
grade (A-F), personal relevance, ease of use, and time to complete. RESULTS:Most
of the respondents were female (71.2%) and African American (93.3%), with amean
age of 43.41 (13.61) years. Many had annual income $25,000 (33.9%) and educa-
tion of high school degree or less (28.8%). Principal components analysis with Va-
rimax rotation showed one factor solutions with eigen values1 - Scale 1: ease of
use of the program (understandability, organization, going through pages, and
printing Jameslink) and Scale 2: relevance of Jameslink (important, interesting,
makes sense, and self-relevant); both scales had excellent internal consistency
(Cronbach’s alphas0.822 and 0.866 respectively). Independent sample t-tests and
chi-square analysis revealed that participants felt Flash providedmore personally-
relevant information and was easier to use compared to HTML. Further, they gave
a better grade to Flash, and Flash took less time to complete (all p’s0.05, adjusted).
Grounded theory analysis found that Flash versionwas clear, concise, informative,
but the layout could be improved whereas HTML version was confusing, stressful,
complicated, and involved toomuch typing. CONCLUSIONS:Althoughwemade an
effort to integrate our familial cancer risk assessment tool in the HTML platform of
a larger, personalized health assessment tool from the university, we found that
our original Flash version was better accepted in this underserved population.
Consideration of human factors is essential to encourage personalized health as-
sessment and understanding of risk status.
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A CROSS-COUNTRY COMPARISON OF SECOND-LINE MULTIPLE MYELOMA
TREATMENTS
Walker SA, Izmirlieva MA, Mehta P
IHS Global Insight, London, UK
OBJECTIVES: This study seeks to compare the actual cost (minus administration
costs) of bortezomibmonotherapy treatment versus lenalidomide/dexamethasone
therapy in second-linemultiplemyeloma (MM) in the United States and the United
Kingdom. It also reviews decisions on second-line MMmade by health technology
assessment (HTA) agencies.METHODS: The IHS OncoInsight Market Access Data-
base was reviewed to find the ex-manufacturing package price and price per mg of
each drug. The average cost per treatment was calculated by multiplying the fac-
tory price per mg by the average total mg per treatment, calculated using the
official dosage and duration of use from the drugs’ labels. All prices were from H1
2010. Additionally, HTA decisions on the drugs were identified. RESULTS: The total
average treatment cost for the lenalidomide/dexamethasone treatment was
$101,052.75 in the United States and £58,926.78 in the United Kingdom.The total
average treatment costs of bortezomibmonotherapy were $17,045.53 and £9,708.2.
Using the highest number of doses documented in the APEX study, the totals come
to $34,091.06 and £19,416.4.The U.K. National Institute for Health and Clinical Ex-
cellence (NICE) has reviewed both therapies in previously treated MM. In October
2007, NICE recommended bortezomib monotherapy for second-line MM. In June
2009, NICE recommended lenalidomide plus dexamethasone in third-line MM.
Both recommendations were subject to a patient access scheme. CONCLUSIONS:
The overall cost of bortezomib monotherapy was found to be potentially lower
than Revlimid plus dexamethasone in second-line MM. Even when taking into
account a higher dose regimen for bortezomib monotherapy, its cost is still signif-
icantly lower than the lenalidomide combination therapy. However, the mode of
administration—injectable versus oral—is likely to be taken into account by pay-
ors. These findings are consistent with NICE, which recommends bortezomib
monotherapy for second-line treatment and lenalidomide combination only for
third-line treatment.
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TRANSFERABILITY OF NICE RECOMMENDATIONS FOR PHARMACEUTICAL
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OBJECTIVES: The health status of the population of Central-Eastern Europe (CEE) is
worse than that of Western Europe, this is especially true for malignant diseases.
Furthermore, these countries have more limited health care resources; therefore,
transparent decision criteria, including the assessment of cost-effectiveness in
formal health technology assessments (HTA), are an absolute necessity. Unfortu-
nately, the number of trained health economists and prospective health economic
trials and the public budget for HTA are not comparable to the major markets of
innovative health technologies, such as those of the United Kingdom. Transferabil-
ity of good quality HTA reports, especially those prepared by the National Institute
for Health and Clinical Excellence (NICE), could be highly beneficial to prevent the
duplication of efforts and to save resources for local health technology
assessments. METHODS: We scrutinized the transferability of 68 published NICE
appraisals of innovative oncological drugs to CEE countries. The most critical fac-
tors influencing the transferability of NICE appraisals were selected based upon
differences in measures between UK and CEE countries RESULTS: In general, we
can conclude that HTA recommendations by the NICE are not transferable. Certain
elements of HTA reports are transferable, but adjustment to local data is absolutely
necessary. If the NICE recommendation is positive, the conclusion can be still
negative in CEE countries; this is primarily due to relative price differences and the
significance of local budget impacts. If the NICE recommendation is negative, the
innovative health technology can be still cost-effective in Central-Eastern Europe
due to the worse health status of the population and the greater potential health
impact on the targeted population. CONCLUSIONS: Decision-makers in CEE coun-
tries cannot make excuses; they must improve the appropriateness of reimburse-
ment decisions to increase the allocative efficiency of health care financing, but
copyingNICE recommendationswithout local adjustmentmay domore harm than
good.
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OBJECTIVES: Minimal health-related quality of life (HRQOL) data have been pub-
lished on patients (pts) withmultiplemyeloma (MM) in the United States (US). This
analysis characterizedHRQOL of ptswith active, symptomaticMMby International
Staging System (ISS) stage and ECOG status. METHODS: Data were collected in
Connect MM®, a prospective US registry initiated in 2009. Clinicians reported on pt
demographics and clinical characteristics. Pts reported HRQOL within twomonths
of diagnosis by completing the Brief Pain Inventory (BPI), EQ-5D, and Functional
Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) instruments. Mean
(Standard Deviation (SD)) BPI, EQ-5D and FACT-MM scores were analyzed by ISS
and ECOG. Statistical significance was ascertained by ANOVA using SAS 9.1.
RESULTS: 640 pts from 189 centers provided data. Pts were predominantly male
(56%) and white (79%) with mean age 66.9 yrs (SD 11.8). Pts were characterized by
evaluable ISS stage (Stage I (107), II (141), III (151), and ECOG status ( 0 (154), 1 (227),
2/3 (76)). Mean (SD) BPI pain was 2.7 (2.5), 3.6 (3.1), 3.9 (2.8) for ISS I, II and III
(p0.0083), and 2.4 (2.7), 3.5 (2.7), 4.5 (3.1) for ECOG 0, 1 and 2/3 (p0.0001). EQ-5D
pain/discomfort and usual activities scores were most compromised. All EQ-5D
domains increased in severity as ECOG became more advanced (p0.0001), while
mobility (p0.0033), self care (p0.0001) and usual activities (p0.0006) increased
in severity as ISS becamemore advanced. Lower FACT-MM physical (p0.0026 and
p0.0001) and functional (p0.0009 and p0.0001) scores were observed with in-
creasing ISS and ECOG severity. CONCLUSIONS: Connect MM® findings indicate
that increasing ISS and ECOG is associated with greater HRQOL degradation. In
particular, physical and functioning domains, pain, and ability to conduct usual
activities and to provide self care requires special attention from clinicians.
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PREDICTING THE FUTURE IMPACT OF EMERGING TECHNOLOGIES ON
HEPATOCELLULAR CARCINOMA (HCC): MEASURING STAKEHOLDERS
PREFERENCES WITH BEST-WORST SCALING
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BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer
and the third leading cause of cancer death worldwide. While a number of tech-
nologies are emerging, little is known about their future impact on this devastating
disease. OBJECTIVES: To explore clinicians’ views on emerging technologies with
respect to their expected impact on HCC outcomes in the next 5 to 10 years.
METHODS: We focused on 11 emerging technologies likely to impact HCC out-
comes as previously identified through qualitative research. A survey was con-
ducted with clinicians considered liver disease and liver cancer experts in Europe,
Asia and the United States. Clinicians’ views on the future impact of these tech-
nologies were explored using best-worst scaling. A balance incomplete block de-
sign (BIBD) with 11 choice tasks was constructed. Each task contained five technol-
ogies. Respondents were asked to identify those technologies that will have the
most and least likely impact on HCC outcomes within 5 to 10 years. Statistical
analysis used sequential best-worst. RESULTS: One hundred and twenty experts in
10 different countries completed the survey. Of these 41%were hepatologist and 65%
described their main area of specialty as HCC. Technologies considered to have the
most impactbyparticipants included: earlydetectionofHCC,molecular targeted ther-
apy, genetic/genomic biomarkers, hepatitis C vaccination and stem cell therapy. Ad-
juvant/Neo-adjuvant therapies, interventional radiology, biopsy-free HCC diagnos-
tics, transplant technology, improved surgical techniques and immunomodulation
were seen as the least important emerging technologies. CONCLUSIONS: This study
demonstrates that preference-based methods, such as best-worst scaling, are val-
ued tools in understanding differences in opinions about the likely impact of
emergingmedical technologies. Such information can be used by policy makers as
part of horizon scanning and as a mean to align research budgets with informed
clinicians’ expectations.
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OBJECTIVES: Empowerment is a multi-faceted construct that, in the cancer con-
text, refers to feelings of being able to manage the challenges of the disease and
gain a sense of control over the cancer experience. Empowerment is a multi-fac-
etted and difficult to measure construct, and few patient empowerment measures
exist for cancer research. We evaluated the psychometrics of the Health Education
Impact Questionnaire (heiQ) evaluation system originally developed for chronic
diseases in Australia. It has been translated into 19 languages, applied across dis-
eases, interventions and healthcare settings. Five of the original 8 scales were
considered conceptually relevant to the empowerment construct in cancer; Emo-
tional wellbeing, Constructive attitudes and approaches, Skill and technique ac-
quisition, Social integration and support, and Health services navigation.
METHODS:We recruited English-speaking Canadians diagnosed 27 months ear-
lier with different types of cancer who were randomly selected from the popula-
tion-based Manitoba Cancer Registry, and from users of the Canadian Cancer So-
ciety telephone support programs. Participants (n731) completed a mailed
questionnaire including the heiQ, other related constructs and demographic ques-
tions. Traditional psychometric analyses andmodern confirmatory factor analysis
(CFA: LISREL) were used to examine psychometric structure and construct validity.
RESULTS:Ordinal CFAwith robustmaximum likelihood estimation gave very good
model fit (2(265)528.17, RMSEA0.038, NNFI0.994, CFI0.995, SRMR0.055).
Factor loadings were moderately high (0.65-0.91). Cronbach alphas were 0.76 to
0.85. A priori hypotheses regarding the magnitude and direction of correlations
between certain heiQ scales and measures of cancer self-efficacy were supported.
CONCLUSIONS: These results provide strong evidence that the five constructs con-
ceptualized as representing key dimensions of empowerment performwell in can-
cer survivors. This is the first formal validation of the heiQ empowerment-related
dimensions in the cancer setting. These scales will fill an important gap in cancer
research and evaluation by providing validated measures of important effects of
cancer information and support interventions.
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WHO CHOSE PRIMARY ANDROGEN DEPRIVATION THERAPY OVER RADICAL
PROSTATECTOMY: A RETROSPECTIVE STUDY AMONG VETERANS WITH
LOCALIZED PROSTATE CANCER
Liu J, Shi L, Sartor O
Tulane University, New Orleans, LA, USA
OBJECTIVES: For localized prostate cancer, both primary androgen deprivation
therapy (PADT) and surgery is frequently used, without any comparative evidence
of survival benefit between them. This retrospective study aimed to examine the
predictors of receiving PADT versus radical prostatectomy (RP) as a monotherapy
among clinically localized prostate cancer patients.METHODS:Male veterans with
localized prostate cancer were identified from the Veterans Affairs Veterans Inte-
grated Service Network (VISN) 16 (01/2004-12/2008). Eligible patients had no other
cancer diagnosis before the first prostate cancer diagnosis and used PADT or RP as
monotherapy within 6 month after first diagnosis. A proxy variable (preference)
was created to account for potential physician influence on treatment choice in
each of the ten medical centers of VISN 16. Predictors fitted in a logistic regression
model included age, race, marital status, non-VA insurance, cancer stage, baseline
prostate specific antigen (PSA), Charlson comorbidity index (CCI), alcohol and to-
bacco use, calendar year at diagnosis, and preference. RESULTS: The analysis sam-
ple included 878 patients, 523 in PADT cohort and 355 in RP cohort. The age [Mean
(SD)] in PADT was 71.4 (8.92) years old, 60.3 (5.91) in RP, p0.001. The significant
predictors of receiving treatment of PADT over RP included being 65 years old or
over (OR9.152, 95% CI: 5.688, 14.725), higher baseline PSA (OR1.184, 95%
CI1.133, 1,237), higher CCI (CCI1: OR2.246, 95% CI1.062, 4.753; CCI2:
OR7.328, 95% CI2.599, 20.665) and preference of PADT (OR4.603, 95% CI3.068,
6.906). Other explanatory variables including race, marital status, cancer stage,
year at diagnosis were not significant (all p-values0.05). CONCLUSIONS: Among
localized prostate cancer patients in VA, age, baseline PSA and CCI were strong
predictors of treatment selection of PADT versus RP. We did not observed a signif-
icant treatment selection patterns change over time as expected.
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ONCOLOGY MEDICATION UTILIZATION BASED ON FEDERAL DRUG
ADMINISTRATION (FDA) LABELING, NATIONAL COMPREHENSIVE CANCER
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AND EVIDENCE FOR PATIENTS WITH ADVANCED NON SMALL CELL LUNG
CANCER (NSCLC): AN ANALYSIS FROM THE NCCN ONCOLOGY OUTCOMES
DATABASE
Lepisto EM1, Vandergrift JL1, Kalemkerian GP2, Pisters KM3, Zornosa C1, Rabin MS4,
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OBJECTIVES: The primary aim was to examine first-line systemic therapy for pa-
tients with advanced NSCLC in relation to concordance with NCCN GLs and FDA
labeling and examine the evidence supporting off-label GL concordant therapies.
METHODS: The cohort included advanced NSCLC patients initiating first-line sys-
temic therapy at one of 8 NCCN institutions from January 2007 through December
2009. GL concordance and off-label use of regimens were examined. Where incon-
sistency between drug labels was observed the more inclusive label was utilized.
For example, carboplatin has no label for NSCLC; however, bevacizumab’s label
directs use in combination with carboplatin and paclitaxel. Bevacizumab’s label
was utilized to characterize carboplatin’s on-label use. RESULTS: Excluding clinical
trial patients (n210) and patients with unknown therapies (n9), 1,121 stage
IIIB/IV patients receiving systemic therapy were identified. Patients were 63 years
old (median), with eithermanaged-care (48%) orMedicare (40%) insurance, andhad
adenocarcinoma (64%). Most had smoking histories (81%). Overall, 84% received GL
concordant therapy; 20% received therapy consistent with FDA labeling. 209 (19%)
patients received GL concordant on-label therapy, 732 (65%) received GL concor-
dant off-label therapy; 18 (2%) patients received GL non-concordant on-label ther-
apy; and 162 (14%) received GL non-concordant off-label therapy. The carboplatin-
paclitaxel-bevacizumab (n132, 63%) and cisplatin-based doublets (n72, 34%)
account for the majority of on-label GL concordant care. Carboplatin-based dou-
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